The Meningioma drugs in development market research report provides comprehensive information on the therapeutics under development for Meningioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Meningioma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Meningioma and features dormant and discontinued products.
GlobalData tracks 33 drugs in development for Meningioma by 31 companies/universities/institutes. The top development phase for Meningioma is phase ii with 13 drugs in that stage. The Meningioma pipeline has 32 drugs in development by companies and one by universities/ institutes. Some of the companies in the Meningioma pipeline products market are: Bristol-Myers Squibb, Chimerix and Merck.
The key targets in the Meningioma pipeline products market include Cells Expressing Somatostatin Receptor Type 2 (SRIF1 or SSTR2), Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22), and Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22).
The key mechanisms of action in the Meningioma pipeline product include Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) Inhibitor with three drugs in Phase II. The Meningioma pipeline products include 13 routes of administration with the top ROA being Oral and seven key molecule types in the Meningioma pipeline products market including Small Molecule, and Monoclonal Antibody.
Meningioma overview
A meningioma is a type of tumor that develops from the meninges, the membrane that surrounds the brain and spinal cord. There are three layers of meninges, called the dura mater, arachnoid, and pia mater. Most meningiomas (90%) are categorized as benign tumors, with the remaining 10% being atypical or malignant. There is no obvious cause of a meningioma. However, this type of brain tumor is about three times more common in women than in men. A meningioma can cause symptoms by pressing on the brain or spinal cord.
For a complete picture of Meningioma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
